“覆盖商保创新药” 复星联合健康保险虚晃一枪

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products covering commercial health insurance innovative drugs was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [1][2][4]. Group 1: Announcement and Withdrawal - Fosun United Health Insurance initially announced that nine of its medical insurance products would cover innovative drugs listed in the newly released commercial health insurance innovative drug directory [1][3]. - The announcement was later deleted from their official WeChat account, with the company stating that the decision to retract was due to ongoing discussions and lack of finalization on the product details [2][3]. Group 2: Market Implications - The release of the commercial health insurance innovative drug directory, which includes 19 high-value innovative drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [5]. - The inclusion of innovative drugs in medical insurance is viewed as a necessary direction for health insurance development, aiming to alleviate patients' financial burdens and improve product competitiveness [6]. Group 3: Financial Performance and Capitalization - Fosun United Health Insurance reported a net profit of 0.63 billion in the first three quarters of the year, continuing a trend of profitability since 2021 [7][8]. - The company has been seeking to increase its registered capital, with a recent approval to raise it from 6.9444 billion to 10.1085 billion, which is expected to enhance its capital strength and support the coverage of innovative drugs [9].